Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: abatacept, Bristol-Myers Squibb.

Francis J Dumont1

  • 1Medor Consulting, 421 Dogwood Avenue, Egg Harbor Twp, NJ 08234, USA. francisj_dumont@yahoo.com

Current Opinion in Molecular Therapeutics
|July 22, 2004
PubMed
Summary

Bristol-Myers Squibb is developing abatacept, a fusion protein, for immunological disorders like rheumatoid arthritis. This potential treatment is currently in phase III clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel pharmacological modulators of autophagy and therapeutic prospects.

Expert opinion on therapeutic patents·2012
Same author

Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.

Current cancer drug targets·2012
Same author

Cytokines: the magic is still there.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fontolizumab Protein Design Labs.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fingolimod. Mitsubishi Pharma/Novartis.

IDrugs : the investigational drugs journal·2005
Same author

ISAtx-247 (Isotechnika/Roche).

Current opinion in investigational drugs (London, England : 2000)·2004

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Autoimmune diseases involve immune system dysregulation.
  • Rheumatoid arthritis, multiple sclerosis, and lupus erythematosus are significant immunological disorders.

Purpose of the Study:

  • To evaluate the efficacy of abatacept for immunological disorders.
  • To assess abatacept as a novel therapeutic agent.

Main Methods:

  • Abatacept, a fusion protein, is under investigation.
  • Phase III clinical trials are being conducted.

Main Results:

  • Clinical trial data is pending.
  • Efficacy and safety profiles are under evaluation.

Conclusions:

  • Abatacept shows potential for treating immunological conditions.
  • Further clinical data will determine its therapeutic role.

Related Experiment Videos